Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

90.62 -2.57 (-2.76%)

Delayed Quote Updated: 12:03 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Spyre Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Topics Regulatory Compliance

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 19, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

February 18, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

January 12, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics' CEO Sells 15,000 Shares ↗

January 11, 2026

This biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a recent SEC filing.

Via The Motley Fool

Topics Regulatory Compliance

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 04, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

November 04, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

October 29, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

October 24, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

October 15, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗

October 14, 2025

Via Benzinga

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

October 13, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

October 13, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 10, 2025

Via Benzinga

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

October 05, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

September 26, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases

September 15, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre (SYRE) Q2 R&D Up 23% Loss Narrows ↗

August 06, 2025

Via The Motley Fool

This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

April 08, 2025

Via Benzinga

SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm

December 03, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 ↗

August 07, 2024

SYRE stock results show that Spyre Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

July 18, 2024

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 ↗

May 09, 2024

SYRE stock results show that Spyre Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday ↗

March 05, 2024

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.

Via Benzinga

Topics Stocks

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.